glutathione shifts melanin to pheomelanin - an overview Frontiers | Research progress on

In uveal melanoma (75,150), ChaC1 is associated with poor overall, progression-free and disease-specific survival and progression-free interval, making it a promising indicator of unfavorable tumor prognosis

Pharmacol Biochem Behav 29 : 343350

10.1016/j.pbb.2006.07.026 373

The dosage chart presented here provides a framework, but the clinical nuances, specifically the titration pace, the dose ceiling, the choice of synergistic agents, and the biomarker monitoring schedule, should be individualized by a physician familiar with both the patient's metabolic history and the evolving evidence base for mitochondrial peptide therapy

It's a bit counterintuitive, but the higher the gauge number, the thinner the needle